Glaxo Contends FDA Ariva Decision Will Confuse Smokers Wanting To Quit
This article was originally published in The Tan Sheet
Executive Summary
FDA's refusal to regulate Star Scientific's Ariva "cigalett" tobacco lozenges could be detrimental to the public health, GlaxoSmithKline Consumer Healthcare asserts